Apollo Health Ventures is an Early Stage Investment Firm interested in accelerating breakthrough scientific discoveries to the clinic by building life science companies around new therapeutic technologies. Apollo Health Ventures focuses on assets with the potential to treat, prevent, or even reverse age-related diseases such as Alzheimer's, Heart Disease, Sarcopenia, Frailty, and Cancer, with the ultimate goal of increasing healthy human lifespan. Apollo invests in early stage companies, works with scientists and entrepreneurs to create new ventures, and engages in hypothesis-driven company building.
Location: Germany, Berlin
Employees: 11-50
Founded date: 2016
Investment Type: Venture Capital
Investment Stage: Pre-Seed; Seed; Series A
Portfolio 3
| Date | Name | Website | Total Raised | Location |
| - | Samsara Th... | samsaratherapeutics.com | $3.2M | United Kin... |
| - | Cleara Bio... | clearabiotech.com | $2.5M | Netherland... |
| - | Aeovian Ph... | aeovian.com | $50M | - |
Mentions in press and media 9
| Date | Title | Description |
| 05.12.2024 | Refoxy Pharmaceuticals Secures €9.1 Million to Tackle Idiopathic Pulmonary Fibrosis | In the bustling world of biotechnology, where innovation meets necessity, Refoxy Pharmaceuticals has emerged as a beacon of hope. The Berlin-based company recently announced a significant funding milestone, raising €9.1 million in a seed ex... |
| 04.12.2024 | Refoxy Pharmaceuticals raises €9.1 million to progress its novel FOXO3 therapeutics for Idiopathic Pulmonary Fibrosis | Investment led by Boehringer Ingelheim Venture Fund, with the participation of new & existing investors, including Apollo Health Ventures, NRW.Venture, & HTGF. COLOGNE, GERMANY, December 4, 2024 /EINPresswire.com/ -- Refoxy Pharmace... |
| 14.10.2022 | Paul Scherrer Institute and Apollo Health Ventures launch Focal Biosciences | |
| 10.02.2022 | New US Laboratory and funding for HAYA Therapeutics | |
| 11.12.2021 | Apollo Health Ventures Closes Fund II, at $180M | Apollo Health Ventures, a Boston, MA and Berlin, Germany-based venture capital firm specialized in developing and investing in data-driven biotechnology and health tech ventures, closed its second venture fund at $180m. . Apollo Health Vent... |
| 01.12.2021 | Apollo Health Ventures Closes $180 Million Fund to Drive Breakthrough Innovations Combating Age-related Diseases | Apollo Health Ventures announces the final closing of its second venture fund to build a portfolio of data-driven biotechnology and healthtech ventures aimed at extending human healthspan. The oversubscribed Apollo Health Ventures Fund II s... |
| 20.05.2021 | HAYA Therapeutics closes CHF 18 million seed round | |
| 20.05.2021 | HAYA Therapeutics closes CHF 18 million seed round | Along side Broadview Ventures, HAYA Therapeutics’ seed round attracted additional investors including Apollo Health Ventures, BERNINA BioInvest, 4See Ventures, Schroder Adveq and Viva BioInnovator. The startup will use the funds from the fi... |
| - | Health and Happiness at Davos 2020 | Photo credit: Bloomberg It was -10 centigrade when I arrived with two colleagues in Davos for the 2020 WEF forum - our team’s first time attending the world-renowned conference. I didn’t really know what to expect. What did transpire is li... |